Aethlon Medical, Inc., a medical device company operating within the Health Care sector, is headquartered in San Diego, United States. The company is dedicated to developing medical devices aimed at the selective removal of disease-promoting particles from the circulatory system. Aethlon Medical focuses on addressing unmet medical needs in areas such as cancer, infectious diseases, and other life-threatening conditions. The company is listed on the Nasdaq stock exchange and trades in USD.
As of February 10, 2026, Aethlon Medical’s stock closed at $2.09, trading near its 52-week low of $2.06, recorded on the same day. This is a significant decline from its 52-week high of $53.60, achieved on February 17, 2025. The stock’s closing price on February 4, 2026, was $2.23, indicating a continued downward trend. The market capitalization of the company stands at approximately $2,025,548 USD.
The company’s financial metrics reveal a price-to-earnings (P/E) ratio of -0.05, indicating negative earnings. Additionally, the price-to-book (P/B) ratio is 0.378, suggesting that the company’s market valuation is below its book value. This financial situation reflects significant price volatility and potential underperformance relative to its balance-sheet fundamentals.
On February 4, 2026, Aethlon Medical announced that it would publish its fiscal third-quarter results and hold a conference call. This announcement is the most recent press release from the company, highlighting its ongoing efforts to communicate with stakeholders regarding its financial performance and strategic direction.
For more detailed information about Aethlon Medical’s products and services, interested parties can visit the company’s website at www.aethlonmedical.com .
